BRAF and lung adenocarcinoma: A Case of Immunotherapy Response to BRAF&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.